Role of the integrin-linked kinase/TGF-β/SMAD pathway in sitagliptin-mediated cardioprotective effects in a rat model of diabetic cardiomyopathy
Journal of Pharmacy and Pharmacology · 2024
DOI: 10.1093/jpp/rgad111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2024. Verfasst von Anfal F Bin Dayel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Ministry of Education in Saudi Arabia.
Abstract (Originalsprache)
Objectives
Diabetic cardiomyopathy is a known complication of diabetes mellitus. Herein, we aimed to determine whether glycemic control mediated by sitagliptin, a dipeptidyl peptidase-4 inhibitor, can ameliorate diabetic myocardial abnormalities by modulating TGF-β signaling via the SMAD and integrin-linked kinase (ILK) pathways.
Methods
Four groups of male Wistar albino rats were used, with six rats in each group. Two nondiabetic and two diabetic (produced by a single intraperitoneal dose of streptozotocin (55 mg/kg)) groups were administered either normal saline or sitagliptin (100 mg/kg) orally for 6 weeks. Subsequently, HW/BW ratios and cardiac enzymes were assessed, along with a histological examination of cardiac tissues. Levels of TGF-β, collagen I, p-SMAD2/3, TNF-α, MMP-9, and ILK were detected.
Results
Compared with the diabetic control group, sitagliptin-treated diabetic rats exhibited considerably reduced HW/BW ratios and troponin I and creatine kinase-MB levels, with improvements in histopathological changes in cardiac tissues. TGF-β, collagen I, p-SMAD2/3, TNF-α, and MMP-9 levels were significantly decreased in the sitagliptin-treated diabetic group, whereas ILK was elevated following sitagliptin treatment.
Conclusion
Sitagliptin could afford cardioprotective effects for the first time by altering ILK-associated TGF-β/SMAD signaling pathways. Thus, sitagliptin may be a promising therapeutic target for the prevention of diabetic cardiomyopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
- College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
ORCID-Profile: Anfal F Bin Dayel, Asma S Alonazi
Förderung
- Ministry of Education in Saudi Arabia
Zitieren
APA
Bin Dayel, A. F., Alonazi, A. S., Alrasheed, N. M., Alamin, M. A., Sarawi, W. S., Alharbi, A. O., Alabbad, N. A., Albuaijan, D. A., Alassiri, D. N., Aljarbua, A. F., Almusaytir, F. K., & Alrasheed, N. M. (2024). Role of the integrin-linked kinase/TGF-β/SMAD pathway in sitagliptin-mediated cardioprotective effects in a rat model of diabetic cardiomyopathy. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgad111
Vancouver
Bin Dayel AF, Alonazi AS, Alrasheed NM, Alamin MA, Sarawi WS, Alharbi AO, et al. Role of the integrin-linked kinase/TGF-β/SMAD pathway in sitagliptin-mediated cardioprotective effects in a rat model of diabetic cardiomyopathy. Journal of Pharmacy and Pharmacology. 2024. doi:10.1093/jpp/rgad111
BibTeX
@article{BinDayel2024,
author = {Bin Dayel, Anfal F and Alonazi, Asma S and Alrasheed, Nawal M and Alamin, Maha A and Sarawi, Wedad S and Alharbi, Abeer O and Alabbad, Nahla'a A and Albuaijan, Danah A and Alassiri, Dareen N and Aljarbua, Alanoud F and Almusaytir, Fatimah K and Alrasheed, Nouf M},
title = {Role of the integrin-linked kinase/TGF-β/SMAD pathway in sitagliptin-mediated cardioprotective effects in a rat model of diabetic cardiomyopathy},
journal = {Journal of Pharmacy and Pharmacology},
year = {2024},
doi = {10.1093/jpp/rgad111}
}
EUVIMED